Model Airplanes

Question-and-Answer Session

Operator

[Operator Instructions] Our first question comes from the line of Steven Meikle of Royal Bank of Canada. Your line is now opened.

Steven Meikle

Maybe just the first question on, Len what you talked about with your $1 billion in prime contracts that are out for award. Can you give us a little bit more color, is this with your traditional customer base? Or is this a lot of new customers? And is this kind of a compilation of quite a few medium-sized contracts? Or are there also some very large sort of strategic awards in those awards that are waiting bid?

Leonard Moodispaw

It’s all the about stated. Just generally with our typical base we have been working over the years and there are some very large ones in there, and some midsize ones, and as you know the way our customers are organized, you can have new customers within that customer. Yes we are expanding to new customers, new adjacencies within those agencies, but it’s of multiple sizes.

Chris Donaghey

Steve this is Chris Donaghey. I would just add, that it’s pretty granular that $1 billion plus is about 69 separate contracts. Again these are to be awarded over the course of 2015 and 2016. So again the point to be made here is that this is the largest backlog of proposal activity that we have seen in the company’s history.

Steven Meikle

And should we read from that that you’re able to bid a different set of awards because of

Article source: http://seekingalpha.com/article/2929236-keyw-holdings-kewy-ceo-leonard-moodispaw-on-q4-2014-results-earnings-call-transcript

Probably two of the most exciting and transformative technologies of our day are drones and 3D printing. Both promise to change the way economies function, businesses operate, and governments interact. Where these two technologies converge we have already seen tremendous innovation, leading to applications which would never have been imaginable just a few years ago.

One company called Krossblade Aerospace Systems has reached out and informed us about their new UAV/drone which has relied heavily on end-use 3D printed components for its production. This isn’t just any typical drone, however. In fact it’s modeled after the company’s 5-seat hybrid 300 mph vertical-take off and landing concept vehicle, called SkyCruiser, which was unveiled last year.

As a means to test the concepts behind the manned SkyCruiser vehicle, Krossblade Aerospace Systems decided to create a smaller UAV/drone model of the aircraft called SkyProwler, and in doing so has turned to Kickstarter (the launch of the campaign is imminent) in order to help fund the project.

“We use the small unmanned SkyProwler to develop the concepts underlying SkyCruiser and have also found it to be an excellent unmanned aerial vehicle, not only for various applications, but also to get people excited about aviation and technology,” explained co-founder and CEO of Krossblade Aerospace Systems, Daniel Lubrich, to 3DPrint.com.

The SkyProwler drone is able to vertically take off in a similar fashion as many of the multi-rotor drones we have seen

Article source: http://3dprint.com/45355/skyprowler-3d-print/

February 17, 2015 | BIOVIA, the life sciences-oriented
subsidiary of Dassault Systèmes formerly known as Accelrys, today introduced a
new informatics platform for companies developing biologic drugs, in an
announcement at the Molecular Medicine Tri Conference in San Francisco. BIOVIA
Biologics is designed as a central repository of data, and workflow management
platform, for programs to discover and develop biologics, navigate the
regulatory process, and prepare these complex biological products for
manufacture at scale.

BIOVIA CEO Max Carnecchia spoke
to Bio-IT World correspondent Aaron
Krol about the challenges to working with this rapidly growing class of
therapies, and the need for IT programs tailored to the needs of biologics.
This interview has been edited for length and clarity.

Bio-IT World: The pharmaceutical industry has
been investing much more in biologics in recent years. How much would you say
this is about the market incentives that exist — less generic competition,
longer exclusivity periods — and how much is the genuine medical promise of
these therapies? 

Max Carnecchia: Not to be controversial, but it’s definitely
a balance of both. The science is there to be able to satisfy unmet clinical
needs. You can point to examples of therapies that have been delivered in the
course of the last four or five years that prove that point quite effectively.
At the same time, biosimilars are very difficult and expensive to develop, and
we’ve yet to see what that means from an approval perspective. From a business
perspective, certainly our customers in the industry want to

Article source: http://www.bio-itworld.com/2015/2/17/biovia-launches-biologics-informatics-program.html